Anabolic steroid
In 1937, clinical trials began using methyltestosterone pills and testosterone propionate injections to treat human patients. Physicians soon discovered these drugs could stimulate bone marrow in people suffering from aplastic anemia or leukemia. For decades, anabolic steroids remained the primary treatment for hypoplastic anemias caused by kidney failure or chronic illness. Pediatric endocrinologists used growth stimulation therapies on children with severe growth failure before recombinant growth hormone became widely available. Doctors prescribed oxandrolone to burn victims recovering from severe trauma, improving both short-term survival and long-term outcomes. Cancer patients receiving chemotherapy often lost significant weight; anabolic steroids helped preserve muscle mass during this wasting process. Postmenopausal women sometimes received nandrolone decanoate to prevent osteoporosis, though virilizing side effects limited its widespread adoption. Elderly men with low testosterone levels were given small doses to increase lean body mass, although a 2006 placebo-controlled trial found no benefit regarding physical performance or quality of life. Some physicians treated idiopathic short stature in boys using low-dose steroids to accelerate height gain. Alcoholic hepatitis patients received specific steroid regimens to improve liver function and overall health. Men experiencing delayed puberty were given androgens to induce male secondary sexual characteristics like facial hair and voice deepening.
Between 1988 and 1993, the International Olympic Committee banned anabolic steroids after Ben Johnson tested positive at the Seoul Summer Games. By 1976, the IOC had already placed these substances on their list of prohibited drugs for competitive athletes. In the United States, between one million and three million people use anabolic steroids without medical supervision. A 2000 study by Blue Cross Blue Shield found that twenty percent of teenagers aged twelve to seventeen used steroids primarily for cosmetic appearance rather than sports competition. Non-competitive bodybuilders make up seventy-eight point four percent of all steroid users according to recent surveys. Only thirteen percent of non-medical users reported unsafe injection practices like sharing needles, though some studies suggest this number is even lower. College students who use steroids often hold post-secondary degrees and earn higher household incomes than the general population. Weightlifters and track-and-field athletes have historically sought performance advantages through synthetic testosterone derivatives. Bodybuilding competitions frequently see participants using multiple compounds simultaneously to maximize muscle size and strength gains. Cycling teams in Europe and North America have faced scandals involving systematic doping programs throughout the twentieth century. Baseball players in Major League Baseball have been linked to steroid use during the early 2000s steroid era. Mixed martial arts fighters sometimes test positive for banned substances despite strict pre-fight testing protocols. The prevalence of steroid use among high school students in the U.S. may reach as high as two point seven percent. Athletes who use these drugs risk disqualification from major sporting events if detected by IOC-accredited laboratories.
A 2010 study by the International Society for Clinical Densitometry ranked anabolic steroids as the fifteenth most dangerous drug overall based on expert consensus. Users frequently develop acne vulgaris or severe acne conglobata due to overactive sebaceous glands stimulated by elevated hormone levels. Cardiovascular damage includes left ventricular hypertrophy, which reduces the heart's ability to pump blood effectively. Hypertension affects many long-term users, especially those with pre-existing high blood pressure conditions. Liver toxicity occurs primarily with oral 17α-alkylated compounds like methyltestosterone and fluoxymesterone. Peliosis hepatis, a rare condition causing blood-filled cysts within the liver, has become increasingly recognized among chronic users. Kidney damage manifests as focal segmental glomerulosclerosis, a type of scarring similar to that seen in morbidly obese patients but often more severe. Testicular atrophy results from suppressed natural testosterone production following prolonged exogenous steroid intake. Women using these drugs face irreversible voice deepening and excessive facial hair growth known as hirsutism. Male users may develop gynecomastia, or enlarged breast tissue, caused by conversion of testosterone into estrogen via aromatase enzyme activity. Mental health consequences include mood swings, irritability, aggression, and occasional episodes of psychosis or suicidal ideation. Depression often follows cessation of use, creating withdrawal symptoms that can last for months. Some studies suggest up to fifty-one percent of bodybuilders report unspecified mood disturbances during active usage periods. Long-term abuse correlates with increased risk of myocardial infarction and sudden cardiac death in young adults.
Anabolic steroids bind directly to androgen receptors located inside cell cytoplasm before diffusing into the nucleus. This binding alters gene expression patterns leading to increased protein synthesis and reduced muscle breakdown. Different compounds exhibit varying affinities for the receptor depending on their molecular structure modifications. Five alpha-reductase converts testosterone into dihydrotestosterone within skin and prostate tissues where this enzyme is highly expressed. Dihydrotestosterone proves three to ten times more potent than testosterone when activating androgen receptors in those specific areas. Skeletal muscle lacks significant 5α-reductase expression, explaining why anabolic effects dominate over androgenic ones there. Aromatase enzymes convert some steroids like testosterone into estradiol, which contributes to gynecomastia development at high doses. Nineteen-nortestosterone derivatives such as nandrolone produce less estrogenic activity because they cannot be aromatized effectively. Thirty-three hydroxysteroid dehydrogenase metabolizes DHT into inactive forms within skeletal muscle tissue. Oral bioavailability depends heavily on whether a compound contains 17α-alkylation groups that resist liver metabolism. Esters attached to the C17β position allow injectable formulations to release free hormone slowly over weeks or months. The Hershberger assay measures anabolic-to-androgenic ratios using rat levator ani muscle weight versus ventral prostate weight gains. Modern research indicates all anabolic steroids retain some degree of androgenicity despite attempts to dissociate these effects completely. Functional selectivity theories suggest differential recruitment of coactivators might explain varying tissue responses across different compounds. Non-genomic mechanisms involving membrane-bound androgen receptors remain hypothetical but potentially relevant to neurological outcomes.
Adolf Butenandt purified fifteen milligrams of androstenone from tens of thousands of liters of urine in 1931. Leopold Ružička synthesized this steroid chemically two years later in Zurich laboratories. Three competing pharmaceutical teams raced to isolate testosterone itself during the mid-1930s, funded by companies based in Germany, Switzerland, and the Netherlands. Karoly Gyula David, E. Dingemanse, J. Freud, and Ernst Laqueur published their findings identifying crystalline male hormone from testicles in May 1935. Butenandt and G. Hanisch described a method for preparing testosterone from cholesterol that same August. Ruzicka and A. Wettstein announced patent applications just one week after the American team's publication. Both scientists received the 1939 Nobel Prize in Chemistry, though Nazi authorities forced Butenandt to decline initially before he accepted it post-war. Clinical trials using methyltestosterone began as early as 1937 involving oral doses administered to human subjects. John Ziegler developed metandienone in response to Soviet weightlifting success during the Cold War era. Ciba Pharmaceuticals marketed Dianabol officially approved by the FDA in 1958 for burn victims and elderly patients. Black market availability surged following widespread off-label use by bodybuilders and weightlifters throughout the 1960s. German researchers experimented with steroids on concentration camp inmates during World War II, though evidence remains unproven regarding systematic military administration. President John F. Kennedy reportedly received steroid injections both before and during his presidential term. The first true anabolic steroid, norethandrolone, emerged at G.D. Searle & Company in 1953 but was not marketed until 1956.
The United States classifies anabolic steroids as Schedule III controlled substances under the Controlled Substances Act enacted in the late 1980s. Simple possession without a prescription carries penalties of up to one year imprisonment for first offenses in federal court. Distribution or intent to distribute punishable by ten years maximum incarceration time for initial violations. Canada lists these drugs under Schedule IV of its Controlled Drugs and Substances Act, making illegal sale punishable by eighteen months jail time. Possession alone does not carry criminal charges in Canadian law unlike other schedules. Australia, Argentina, Brazil, and Portugal prohibit non-prescription access entirely through national legislation. Class C Controlled Drug status applies within the United Kingdom restricting availability strictly. Mexico and Thailand allow over-the-counter sales without requiring physician authorization in many regions. Operation Raw Deal conducted by the U.S. Drug Enforcement Administration intercepted thousands of pills in September 2007 targeting black market distributors. Nearly eighty-three thousand Canadians between ages eleven and eighteen used steroids according to a 1993 study by the Canadian Centre for Drug-Free Sport. Researchers concluded student athlete usage remains extremely widespread despite legal restrictions. International treaties increasingly coordinate efforts to detect doping substances using gas chromatography-mass spectrometry techniques. Countries vary significantly in enforcement rigor depending on political priorities and resource allocation toward public health initiatives.
Continue Browsing
Common questions
When did clinical trials begin using anabolic steroids to treat human patients?
Clinical trials began using anabolic steroids to treat human patients in 1937. Physicians used methyltestosterone pills and testosterone propionate injections to treat conditions like aplastic anemia or leukemia during this period.
What are the primary medical uses of anabolic steroids for treating specific diseases?
Anabolic steroids serve as treatments for hypoplastic anemias caused by kidney failure, severe growth failure in children, and muscle wasting in cancer patients receiving chemotherapy. Doctors also prescribe these drugs to burn victims to improve survival rates and to postmenopausal women to prevent osteoporosis.
How many people use anabolic steroids without medical supervision in the United States?
Between one million and three million people use anabolic steroids without medical supervision in the United States. A 2000 study found that twenty percent of teenagers aged twelve to seventeen used these substances primarily for cosmetic appearance rather than sports competition.
Which scientists discovered and synthesized the first anabolic steroids in the 1930s?
Adolf Butenandt purified fifteen milligrams of androstenone from urine in 1931, and Leopold Ružička synthesized this steroid chemically two years later. Karoly Gyula David, E. Dingemanse, J. Freud, and Ernst Laqueur published findings identifying crystalline male hormone from testicles in May 1935.
What legal penalties apply to simple possession of anabolic steroids under US federal law?
The United States classifies anabolic steroids as Schedule III controlled substances under the Controlled Substances Act enacted in the late 1980s. Simple possession without a prescription carries penalties of up to one year imprisonment for first offenses in federal court.